Japanese patent application 2019-005811 is accepted for grant
The Japan Patent Office has issued a notice of allowance confirming that the Japanese Patent Application no. 2019-005811 regarding 177-Lu Labeled peptide conjugate for site specific uPAR-targeting will be granted.This patent application relates to Curasight’s therapeutic technology uTREAT[®] and uses thereof. More specifically the invention relates to human uPAR targeted radionuclide therapy, which enables local irradiation of cancer with almost no irradiation of healthy tissue. Together with uTRACE[®] the combination is known as uPAR Theranostics – the combination of therapy and